Composition for reducing new-onset diabetes

Abstract

A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.

1 . A method for improving abnormal glucose tolerance or obesity of a subject administered a statin, the method comprising administering a pharmaceutical composition containing at least one member selected from the group consisting of eicosapentaenoic acid and its pharmaceutically acceptable salts and esters as its effective component to the subject. 
     
     
         2 . The method according to  claim 1 , wherein the subject has a fasting blood glucose of at least from 110 mg/dL to less than 126 mg/dL. 
     
     
         3 . The method according to  claim 1 , wherein the patient has a serum HDL cholesterol concentration of less than 40 mg/dL. 
     
     
         4 . The method according to  claim 1 , wherein the patient simultaneously suffers from low HDL cholesterolemia. 
     
     
         5 . The method according to  claim 3 , wherein the patient has a serum triglyceride concentration of at least 150 mg/dL. 
     
     
         6 . The method according to  claim 1 , wherein the patient simultaneously suffers from hypertriglyceridemia. 
     
     
         7 . The method according to  claim 1 , wherein the patient has been identified as having impaired glucose tolerance or obesity. 
     
     
         8 . The method according to  claim 1 , wherein at least one member selected from the group consisting of eicosapentaenoic acid and its pharmaceutically acceptable salts and esters is ethyl eicosapentate or eicosapentaenoic acid.